OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Simon on the Evaluation of Datopotamab Deruxtecan in TROP-2–Expressing Solid Tumors

July 13th 2022

George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.

Dr. Kim on the Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

July 13th 2022

Edward S. Kim, MD, MBA, discusses the importance of trastuzumab deruxtecan in HER2-mutated non–small cell lung cancer.

Dr. Peled on the Rationale of Evaluating Lenvatinib/Pembrolizumab with Chemotherapy in NSCLC

July 13th 2022

Nir Peled, MD, PhD, FCCP, discusses the rationale of evaluating the combination of lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Dr Han on the Significance of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

July 13th 2022

Heather Han, MD, discusses breakthrough data from the phase 3 DESTINY-Breast04 trial.

Dr. Jain on Potential Biomarkers in HR-Positive, HER2-Negative Breast Cancer

July 13th 2022

Amit Jain, MD, discusses the potential role of emerging biomarkers in selecting treatment with CDK7 inhibitors in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Dr. Desai on Expanding Options for Cisplatin-Ineligible Bladder Cancer

July 13th 2022

Neil Desai, MD, discusses the variety of options available for patients with localized urothelial cancer who are ineligible for cisplatin-based chemoradiation.

Dr. Ross on the Rise of Colon and Rectal Cancer in Young Patients

July 12th 2022

Howard M. Ross, MD, discusses the increase in colon and rectal cancer in young patients.

Dr. Bidard on the Importance of Elacestrant in ER+/HER2- Breast Cancer

July 12th 2022

Francois-Clement Bidard, MD, PhD, discusses the importance of elacestrant in estrogen receptor–positive, HER2-negative, advanced or metastatic breast cancer.

Dr. Sandhu on Findings with Niraparib in Metastatic Prostate Cancer

July 12th 2022

Shahneen Sandhu, MD, discusses findings with niraparib in metastatic prostate cancer from the phase 3 MAGNITUDE trial.

Dr. Barata on the Challenges of Treating Advanced Urothelial Carcinoma

July 11th 2022

Pedro C. Barata, MD, MSc, discusses challenges associated with treating advanced urothelial carcinoma.

Dr. Hays on Treatment Options in HER2-Positive CRC

July 11th 2022

John L. Hays, MD, PhD, discusses expanding treatment options for HER2-positive colorectal cancer.

Dr. Markowski on the Evaluation of Sabizabulin in mCRPC

July 11th 2022

Mark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

Women in Oncology: Career Obstacles Turned Into Opportunities

July 11th 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, share the challenges they chose to mold into career goals, including developing a new technology to study cell cytokinetics, identifying gene phenotypes, and recognizing that leukemia diseases stem from the same root issues in DNA.

Dr. Jonasch on the Investigation of Belzutifan in ccRCC

July 8th 2022

Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.

Dr. Hays on the Importance of Genetic Testing in Colorectal Cancer

July 8th 2022

John L. Hays, MD, PhD, discusses the importance of genetic testing in colorectal cancer.

Women in Oncology: How Leukemia Treatment has Changed and Stayed Stagnant Over the Years

July 8th 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.

Dr. Rajdev on Detecting HER2 Positivity in GI Cancer

July 7th 2022

Lakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.

Dr. Brenner on the Role of Trastuzumab Deruxtecan in Gastric Cancer

July 7th 2022

Warren S. Brenner, MD, discusses the utilization of fam-trastuzumab deruxtecan-nxki (Enhertu) as a HER2-directed therapy in gastric cancer.

Dr. Elamin on NRG1 Fusions in Solid Tumors

July 7th 2022

Yasir Y. Elamin, MD, discusses NRG1 fusions in solid tumors.

Dr. Vidal on the Lasting Impact of the KATHERINE Trial in HER2-Positive Breast Cancer

July 7th 2022

Gregory Vidal, MD, PhD, discusses the impact of the phase 3 KATHERINE trial in HER2-positive breast cancer.